Viewing Study NCT02437500

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 12:17 PM
Ignite Modification Date: 2026-02-22 @ 7:04 AM
Study NCT ID: NCT02437500
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2023-06-13
First Post: 2015-05-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Sponsor: Seres Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Clostridioides Difficile Infection View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Clostridioides Difficile Infection View
None Gastrointestinal Diseases View
None Digestive System Diseases View
None Intestinal Diseases View
None Gram-Positive Bacterial Infections View
None Communicable Diseases View